Tenaya to Unveil New One-Year Phase 1b/2 TN-401 Gene Therapy Data at ASGCT
Summary
Tenaya Therapeutics announced it will deliver a late-breaking oral presentation of new clinical data from its RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15, 2026. The presentation will include one-year results from Cohort 1 and early data from Cohort 2, detailing safety, biopsy, and efficacy for TN-401 in adults with PKP2-Associated ARVC. This announcement creates a significant near-term catalyst for the clinical-stage biotech, as the progress of its lead gene therapy candidate is crucial for its valuation. While the company recently expanded its equity incentive plan, the market's focus will now shift to the upcoming data readout, which could materially impact the stock given the company's reliance on pipeline success.
At the time of this announcement, TNYA was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.9M. The 52-week trading range was $0.36 to $2.35. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.